FULLY NATIVE MEMBRANE PROTEINS ON EXOSOMES
TO OVERCOME UNDRUGGABLE TARGETS

Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research on bio-drug development technology using exosomes.

Ciloa’s technology allows to address oncology, infectiology, cardiology, genetic and neurological diseases, and more.

Our technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load exosomes with cytosolic proteins as well. It thus makes it possible to reach the most difficult families of membrane protein targets, known as “undruggable”, some being the most promising for therapies.

Ciloa takes advantage of the natural properties of exosomes; they are natural immuno-stimulators, biocompatible, intercellular membrane messengers, and able to cross all the human body barriers including the blood-brain barrier.

MORE ABOUT CILOA

COMPANY

Ciloa exosomes offer a disruptive way to develop a new generation of high-potential therapies.

TECHNOLOGY

Our unique technology allow to produce any type of membrane protein (including GPCR and more.) with their fully native conformation on exosomes outside the cell.

APPLICATIONS

Therapeutic and preventive vaccines, monoclonal antibodies, immunotherapies, and therapeutic vectors carrying drug cargo

WORKING WITH US

Ciloa is uniquely positioned to support your scientific project with membrane proteins on exosomes and close partnerships with academic technology platforms and dedicated biotech structures.

LATEST NEWS

Ciloa @Vivatech 2021

Ciloa is pleased to join its partner Sanofi at the Viva Technology Conference 2021, the world’s rendezvous for startups and leaders…
Read More
Read more news
Menu